newsfilter
← Latest News
Business Wire·

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

Ajax Therapeutics, Inc. and Schrödinger, Inc. (NASDAQ:SDGR) today announced an expansion of their exclusive research collaboration to include a new Janus kinase (JAK) target. The partnership was established in 2019 with